The 4ᵗʰ Wet AMD & Diabetic Eye Disease Drug Development Summit is returning to Boston this upcoming March to unite 70+ industry-based retinal vascular experts from the likes of Bayer, Boehringer Ingelheim, Genentech, Novartis and OcuTerra, at the only industry-dedicated forum to transform the potential of treatment of chronic, sight-threatening retinal vascular diseases to improve patient outcomes.

New additions for 2024 include:

• Fresh perspectives from the new companies speaking at the 2024 meeting including Aviceda Therapeutics, Bayer, Boehringer Ingelheim, OcuTerra, Novartis, Genentech, and Adverum Biotechnologies
• 16+ brand-new speakers out of the 18+ speaker faculty consisting of industry experts and academic leaders working on preclinical models, choroidal neovascularization, retinal inflammation, durable drug delivery to the retinal vascular system and more
• Robust new content focusing on industry-specific topics such as new targets, in vivo and in vitro models, retinal imaging and clinical biomarkers and new modalities for retinal and choroidal neovascularization

To know more visit: https://ter.li/cjnu7k